Back to top
more

AbbVie (ABBV)

(Real Time Quote from BATS)

$201.51 USD

201.51
3,363,153

-0.17 (-0.08%)

Updated Nov 6, 2024 03:44 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (59 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

AbbVie (ABBV) closed at $137.62 in the latest trading session, marking a -1.29% move from the prior day.

Lilly (LLY), Incyte's Olumiant Gets FDA Nod for Alopecia Areata

by Zacks Equity Research

Lilly (LLY) and Incyte's Olumiant is the first-ever FDA-approved systemic treatment for alopecia areata patients.

The Zacks Analyst Blog Highlights Berkshire Hathaway, AbbVie, TotalEnergies, Linde and AT&T

by Zacks Equity Research

Berkshire Hathaway, AbbVie, TotalEnergies, Linde and AT&T have been included in this Analyst Blog.

Sheraz Mian headshot

Top Analyst Reports for Berkshire Hathaway, AbbVie & TotalEnergies

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway Inc. (BRK.B), AbbVie Inc. (ABBV), and TotalEnergies SE (TTE).

Should You Invest in the VanEck Pharmaceutical ETF (PPH)?

by Zacks Equity Research

Sector ETF report for PPH

AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

AbbVie (ABBV) closed the most recent trading day at $146.53, moving -0.43% from the previous trading session.

AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research

AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Amgen (AMGN) Ahead of Industry This Year So Far: What's Next?

by Zacks Equity Research

Amgen's (AMGN) key drugs like Prolia, Repatha, Xgeva and biosimilars are driving sales. Amgen is also rapidly advancing its robust pipeline of early and late-stage assets.

SpringWorks (SWTX) Down Despite Desmoid Tumors Study Meeting Goal

by Zacks Equity Research

SpringWorks' (SWTX) phase III study evaluating its investigational candidate, nirogacestat, in adult patients with progressing desmoid tumors, meets primary and key secondary endpoints.

Neena Mishra headshot

Why High Dividend ETFs are Beating the Market

by Neena Mishra

We highlight 3 ETFs with juicy dividend yields and excellent performance

Benjamin Rains headshot

3 Great Dividend Stocks to Buy Now and Hold

by Benjamin Rains

The episode explores three strong dividend-paying stocks from three different areas of the economy that investors might want to consider buying during the market downturn and holding for the long run.

AbbVie (ABBV) Files NDA for Parkinson's Disease Candidate

by Zacks Equity Research

AbbVie (ABBV) submits a new drug application to the FDA for ABBV-951, which has been developed for treating advanced Parkinson's disease.

Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Nod to PFE COVID Jab for Age 5-11 & LLY's Tirzepatide

by Kinjel Shah

FDA grants emergency approval to Pfizer's COVID-19 vaccine for use in children 5- to 11-year old and approves Lilly's (LLY) novel diabetes treatment, Mounjaro (tirzepatide).

Vertex (VRTX) Outperforms Industry This Year So Far: Here's Why

by Zacks Equity Research

Vertex's (VRTX) cystic franchise sales continue to grow. Vertex has a broad clinical non-CF pipeline, which is progressing rapidly.

AbbVie (ABBV) Buys Option Rights to NextGen Inflammation Drug

by Zacks Equity Research

AbbVie (ABBV) receives the option to license worldwide rights for certain IL-2 muteins, including the next-generation inflammatory candidate, CUG252 from Cugene

Kinjel Shah headshot

Pharma Stock Roundup: PFE's Biohaven Buyout Offer, BAYRY's Q1 Earnings Update

by Kinjel Shah

Pfizer (PFE) is set to buy migraine drugmaker, Biohaven Pharmaceuticals for $11.6 billion. Bayer (BAYRY) beats Q1 earnings and sales expectations.

    AbbVie's (ABBV) Rinvoq Meets Crohn's Disease Study Goals

    by Zacks Equity Research

    AbbVie's (ABBV) Rinvoq achieves statistical significance with its co-primary endpoints of clinical remission and endoscopic response in a late-stage study for Crohn's disease.

    Lilly's (LLY) Olumiant Gets Full Approval From FDA for COVID

    by Zacks Equity Research

    The FDA grants full approval to Lilly (LLY) and Incyte for COVID-19 in certain hospitalized adults. Olumiant is already authorized for emergency use for this indication since November 2020.

    The Zacks Analyst Blog Highlights AbbVie, Qualcomm, Linde, CVS Health Corp, and Booking Holdings

    by Zacks Equity Research

    AbbVie, Qualcomm, Linde, CVS Health Corp, and Booking Holdings are part of Zacks top Analyst Blog.

    Should First Trust Morningstar Dividend Leaders ETF (FDL) Be on Your Investing Radar?

    by Zacks Equity Research

    Style Box ETF report for FDL

    Sheraz Mian headshot

    Q1 Earnings Scorecard and Analyst Reports for AbbVie, QUALCOMM & Linde

    by Sheraz Mian

    Today's Research Daily features a real-time update on the Q1 earnings season and new research reports on AbbVie (ABBV), QUALCOMM (QCOM), and Linde(LIN).

    Reata (RETA) Q1 Earnings Top, Omaveloxolone MAA Likely in Q4

    by Zacks Equity Research

    Reata (RETA) reports a narrower-than-expected loss for the first quarter of 2022 while revenues miss estimates.

    Ironwood (IRWD) Q1 Earnings Miss, Linzess Growth Continues

    by Zacks Equity Research

    Ironwood (IRWD) witnesses strong year-over-year sales growth on continued demand for Linzess. Its first-quarter earnings miss estimates. The company maintains revenue guidance for 2022. Stock declines.